Bright Minds Biosciences Inc. · CSE:DRUG
Bright Minds Biosciences — Investor Presentation (March 2026)
31 slides from Bright Minds Biosciences's investor presentation, March 2026
Slide 1: Novel Drugs for Targeted Treatment of CNS & Neuropsychiatric Disorders
Novel Drugs for Targeted Treatment of CNS & Neuropsychiatric Disorders //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// March 2026 NASDAQ: DRUG | BRIGHTMINDSBIO.COM
Slide 2: Disclaimer and Cautionary Note regarding Forward Looking Statements
Disclaimer and Cautionary Note regarding Forward Looking Statements This corporate presentation (this “Presentation”) of Bright Minds Biosciences Inc. constitute forward-looking information. Forward-looking information contained in matters; and (xxix) market competition, including the prices, produc
Slide 3: Bright Minds is a clinical-stage biotechnology company
Bright Minds is a clinical-stage biotechnology company focused on developing next-generation serotonergic treatments for patients with neurological and psychiatric disorders Proprietary platform of highly selective 5-HT2A and 5-HT2C agonists //////////////////////////////////////////// Robust pipeli
Slide 4: Creating New Chemical Entities That Target Serotonin Signaling
Creating New Chemical Entities That Target Serotonin Signaling Key 5-HT2 Receptors Targets 5-HT2C 5-HT2A/2C 5-HT2A Agonists Agonists Agonists Epilepsy, Impulsivity Depression, Anxiety, Depression, PTSD control, Hyperphagia Pain, Migraine Serotonin (5-HT) is the most prominent neurotransmitter in the
Slide 5: Pipeline
Pipeline Rich and diverse portfolio in neurology and psychiatry with multiple programs Lead Indications Research Phase 1 Phase 2 Phase 3 5-HT2C agonists Registrational trials in DEE BMB-101 DEE Clinical Studies – Phase 2 topline announced Absence seizures Registrational trials in absence seizures BM
Slide 6: Epilepsy Program
Epilepsy Program //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// BMB-101 Novel 5-HT2C Selective Agonist NASDAQ: DRUG | BRIGHTMINDSBIO.COM
Slide 7: BMB-101 demonstrates efficacy in drug resistant Absence Seizures and DEE
BMB-101 demonstrates efficacy in drug resistant Absence Seizures and DEE Absence Seizures DEE -73.1% -63.3% Median reduction of absence seizures ≥ 3s Median reduction in major motor seizures as measured by 24h EEG as measured by seizure diary Topline data from the Phase 2 study NASDAQ: DRUG | BRIGHT
Slide 8: High unmet need beyond DEE
High unmet need beyond DEE Addressable targets for BMB-101 range across multiple epilepsies Mixed Acute Seizure Therapy / Prodromes Medically Controllable Other DEE Targeted by Syndromes Dravet 70% fenfluramine and TSC Infantile Spasms bexicaserin Lennox – Gastaul Syndrome Autoimmune epilepsy Can be
Slide 9: BMB-101 is uniquely positioned to address major unmet needs in epilepsy
BMB-101 is uniquely positioned to address major unmet needs in epilepsy Proof of mechanism Highly selective The only G protein-biased Safety and PK/PD properties demonstrated in Ph.1 Increased 5-HT2C agonist 5-HT2C agonist validated in Phase 1 gamma-power on qEEG Compound 5-HT2A 5-HT2B 5-HT2C 1300 1
Slide 10: Novel 5-HT2C mechanism to avoid tolerance pathways
Novel 5-HT2C mechanism to avoid tolerance pathways Beta-arrestin activation is associated with receptor desensitization and the development of tolerance. BMB-101 is designed to avoid b-arrestin activation and produce sustained effect. Potential for improved efficacy with a G-protein biased agonist F
Slide 11: BMB-101 – Novel scaffold 5-HT2C agonist
BMB-101 – Novel scaffold 5-HT2C agonist Fenfluramine/ BMB-101 Bexicaserin Norfenfluramine Lack of 5-HT2B liability (related to cardiac toxicity) ✓ x ✓ 5-HT2C Biased Agonism ✓ x x (Sustained efficacy) Can be Dose-optimized ✓ x x Increased Frontal Gamma ✓ Not reported Not reported power on qEEG Dosing
Slide 12: BMB-101 Phase 1 study
BMB-101 Phase 1 study Favorable Safety & Tolerability Results Observed Safety and tolerability • No SAEs observed, all AEs were transient. Most common adverse effect - oral paresthesias (related to the sweet taste of the drug product) • Most common on target AE – Headache, Nausea and photophobia o C
Slide 13: BMB-101 Ph.2 study in adult patients with Absence Seizures or DEE
BMB-101 Ph.2 study in adult patients with Absence Seizures or DEE An Open-Label Phase 2 Study To Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults Absence Seizures Arm DEE Arm Seizure frequency measured using 24h ambulatory EEG Seizure frequency measured by seizure diary Key entry
Slide 14: First drug to demonstrate efficacy in Absence Seizures using objective 24h EEG measures
First drug to demonstrate efficacy in Absence Seizures using objective 24h EEG measures Seizure Burden – sum of individual seizures on EEG with a duration of ≥3s Absence Seizures • Patients with uncontrolled absence seizures • Seizures are counted based on 2x24h ambulatory EEG recordings done at bas
Slide 15: Robust reduction of Absence Seizures regardless of seizure duration
Robust reduction of Absence Seizures regardless of seizure duration Reduction in Absence Seizures ≥3s (N=11) ≥5s (N=9) ≥15s (N=4) -73.1% -74.4% -69.2% -74.7% -80.3% -81.8% Change in seizures Change in seizure burden Topline data N – number of patients with seizures of specific duration (≥3, ≥ 5, ≥ 1
Slide 16: BMB-101 improves REM sleep in patients with Absence Seizures
BMB-101 improves REM sleep in patients with Absence Seizures without increasing sleep duration REM sleep duration, minutes Overall sleep duration, hours Increase in REM sleep 120 10 duration 106.7 9.1 8.9 100 8 80 6 +90% 60 56.2 4 40 2 20 0 0 Baseline BMB-101 Baseline BMB-101 Topline data Data avail
Slide 17: Significant decrease in seizures in highly refractory DEE patients
Significant decrease in seizures in highly refractory DEE patients Reduction in Major Motor Seizures LGS DEE other LGS* LGS Dravet* LGS LGS Rett 16.8% -60.3% -76.1% -47.3% -52.3% -73.3% -95.5% -100% Median reduction in Major Motor Seizures As measured by Seizure Diary Dravet patient previously faile
Slide 18: BMB-101 is well-tolerated and safe in patients
BMB-101 is well-tolerated and safe in patients • Most of the TEAEs were mild (about 80%) • No significant changes on vital signs, labs or ECG • Three SAEs – all non drug-related: fractured shoulder with opiate-related drowsiness (2); and pneumonia (1) Relation Relation Adverse Total Total to drug to
Slide 19: Summary
Summary Absence Seizures • BMB-101 was safe and well tolerated in patients with DEE and Absence Seizures -73.1% • BMB-101 met both primary and secondary endpoints in DEE and Absence Seizures DEE • BMB-101 demonstrates a potentially best-in-class profile for patients with refractory DEE and Absence S
Slide 20: Prader-Willi Syndrome
Prader-Willi Syndrome //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// 5-HT2C Selective Agonists NASDAQ: DRUG | BRIGHTMINDSBIO.COM
Slide 21: PWS is a complex neurodevelopmental and neurobehavioral disorder
PWS is a complex neurodevelopmental and neurobehavioral disorder Hyperphagia Serotonin pathway Obesity Feeding problems Executive functions: cognitive and behavioural Compulsion issues Sleep Disturbances Aggression Cognitive impairment Reward system: hyperphagia Self-injury Anxiety Epilepsy Satiety
Slide 22: 5-HT2C agonism directly targets underlying pathophysiology of PWS
5-HT2C agonism directly targets underlying pathophysiology of PWS • PWS patients suffer from loss of part of the paternal chromosome 15 – leading to 5HT2CR loss of function • 5-HT2C receptors are Apex regulators of the neuroendocrine axis. • PWS patients express lower levels of mature, functional, 5
Slide 23: Initiation of Prader-Willi Clinical Program
Initiation of Prader-Willi Clinical Program Bright Minds has initiated clinical development of BMB-105, 5-HT2C agonist specifically for Prader- Willi patients BMB has initiated Phase 2a – Proof-of-Pharmacology program in Prader Willi Syndrome with BMB-101 to pave the way forward for a pivotal study
Slide 24: Potential for best-in-class 5-HT2C agonist directly targeting pathophysiology in PWS
Potential for best-in-class 5-HT2C agonist directly targeting pathophysiology in PWS Clinical • Previously approved as weight loss drugs (lorcaserin and fenfluramine) 5-HT2C agonists • Fenfluramine reduced hyperphagia and improved behaviors in a pilot clinical trial in PWS Efficacy in multiple anima
Slide 25: NOVA: BMB-101 Phase 2a for Prader-Willi Syndrome
NOVA: BMB-101 Phase 2a for Prader-Willi Syndrome Proof-of-pharmacology study to demonstrate that 5-HT2C agonism will address symptom complex in PWS patients Eating behaviours PWS HQ-CT (Hyperphagia) As measured by instruments well accepted in the the PWS research community and regulatory bodies Set
Slide 26: NOVA PWS study design
NOVA (Neuro-Obesity Validated Advancement) PWS study design Dose increase if drug is well tolerated Weight-based dosing Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 2 mg/kg BID Open Label Extension – Visits Q3M 1.67 mg/kg BID Visit 10 Follow-Up* 1.33 mg/kg BID Wash-Out* En
Slide 27: Novel mechanism for Prader Willi Syndrome
Novel mechanism for Prader Willi Syndrome Setmelanotide BMB-10x Vykat (Soleno) Carbetocin (Acadia) ARD-101 (Aardvark) GLP-1 agonists (Rhythm) Targeting hyperphagia ✓ ✓ ✓ ✓ ✓ ? Targeting behavioural issues ✓ x ✓ x ? x Targeting cognitive issues ✓ x x x ? x Twice daily-once a Twice/once daily Intranas
Slide 28: Attractive biologic rationale
Attractive biologic rationale Directly targeting PWS pathophysiology • Genetic link, preclinical and clinical evidence supports potential for targeting the PWS symptom complex with 5-HT2C agonism • Demonstrated tolerability and safety in Phase 1 clinical trial • Hyperphagia and Behavioral endpoints
Slide 29: With only two drugs approved there is significant market opportunity
With only two drugs approved there is significant market opportunity 1/15 000 births1 ~$4.6bn U.S. market size 10,000 – 20,000 PWS patients in U.S.2 Based on the annual price of ~400,000 approved therapy3 cases worldwide Additional research needed to assign a product-specific peak sales estimate Ref
Slide 30: Opportunities for other BMB 5-HT2 agonists
Opportunities for other BMB 5-HT2 agonists //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// NASDAQ: DRUG | BRIGHTMINDSBIO.COM 30
Slide 31: BMB-201 and 202 – potential for best-in-class 5-HT2A agonists
BMB-201 and 202 – potential for best-in- class 5-HT2A agonists BMB-201 BMB-202 Potent inducer of neuroplasticity The most selective 5-HT2A agonist in development* DESCRIPTION ✓ Designed to have minimal or absent psychoactive effects ✓ Designed to have short psychoactive effects time ✓ Efficacy in ro
Bright Minds Biosciences — Investor Presentation (March 2026) on 6ix